Rabbit anti-thymocyte globulin in liver transplantation: All that glitters is not gold, but 1000 patients are so many to dazzle

Liver Transplantation

Volumn 18, Issue 7, 2012, Pages 755-760

  Berenguer, Marina ^a,b,c   Pons, José Antonio ^b,d,e  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^e UNIVERSITY OF MURCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN; DACLIZUMAB; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

CANCER RECURRENCE; CYTOMEGALOVIRUS INFECTION; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LOW DRUG DOSE; MYCOSIS; PERIOPERATIVE PERIOD; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SURVIVAL RATE;

ADULT; ANIMALS; ANTILYMPHOCYTE SERUM; BIOPSY; CASE-CONTROL STUDIES; CLINICAL TRIALS AS TOPIC; END STAGE LIVER DISEASE; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MIDDLE AGED; RABBITS; RECURRENCE;

EID: 84863914953     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23432     Document Type: Review

References (41)

1. Starzl TE, Fung JJ,. Themes of liver transplantation. Hepatology 2010; 51: 1869-1884.
2. Thuluvath PJ, Guidinger MK, Fung JJ, Johnson LB, Rayhill SC, Pelletier SJ,. Liver transplantation in the United States, 1999-2008. Am J Transplant 2010; 10 (pt 2): 1003-1019.
3. 2009 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1999-2008. Accessed March 2012.
4. Burra P, Freeman R,. Trends in liver transplantation 2011. J Hepatol 2012; 56 (suppl 1): S101-S111.
5. Watt KD,. Metabolic syndrome: is immunosuppression to blame? Liver Transpl 2011; 17 (suppl 3): S38-S42.
6. Kawahara T, Asthana S, Kneteman NM,. m-TOR inhibitors: what role in liver transplantation? J Hepatol 2011; 55: 1441-1451.
7. Durand F,. Hot-topic debate on kidney function: renal-sparing approaches are beneficial. Liver Transpl 2011; 17 (suppl 3): S43-S49.
8. Friman S, Arns W, Nashan B, Vincenti F, Banas B, Budde K, et al. Sotrastaurin, a novel small molecule inhibiting protein-kinase C: randomized phase II study in renal transplant recipients. Am J Transplant 2011; 11: 1444-1455.
9. Garcia-Valdecasas JC, Feng S, Lake JR, Vargas HE, Wekerle T, Meadows-Shropshire S, et al. Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II study [abstract]. Liver Transpl 2011; 17 (suppl 1): S79.
10. Neuberger JM, Mamelok RD, Neuhaus P, Pirenne J, Samuel D, Isoniemi H, et al.; for ReSpECT Study Group. Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study. Am J Transplant 2009; 9: 327-336.
11. Boudjema K, Camus C, Saliba F, Calmus Y, Salamé E, Pageaux G, et al. Reduced-dose tacrolimus with mycophenolate mofetil vs. standard-dose tacrolimus in liver transplantation: a randomized study. Am J Transplant 2011; 11: 965-976.
12. Mangus RS, Fridell JA, Vianna RM, Kwo PY, Chen J, Tector AJ,. Immunosuppression induction with rabbit anti-thymocyte globulin with or without rituximab in 1000 liver transplant patients with long-term follow-up. Liver Transpl 2012; 18:786-795.
13. European Liver Transplant Registry. Accessed March 2012.
14. Berenguer M, Charco R, Pascasio JM, Herrero JI,; for Sociedad Española de Trasplante Hepático. Spanish Society of Liver Transplantation (SETH) consensus recommendations on hepatitis C virus and liver transplantation. Liver Int 2012 Jan 4. DOI: 10.1111/j.1478-3231. 2011.02731.x. [Epub ahead of print].
15. Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A,; for OLT for HCC Consensus Group. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012; 13: e11-e22.
16. Thuluvath PJ, Krok KL, Segev DL, Yoo HY,. Trends in post-liver transplant survival in patients with hepatitis C between 1991 and 2001 in the United States. Liver Transpl 2007; 13: 719-724.
17. Neuberger J,. The introduction of MELD-based organ allocation impacts 3-month survival after liver transplantation by influencing pretransplant patient characteristics. Transpl Int 2009; 22: 979-981.
18. Weismüller TJ, Fikatas P, Schmidt J, Barreiros AP, Otto G, Beckebaum S, et al. Multicentric evaluation of Model for End-Stage Liver Disease-based allocation and survival after liver transplantation in Germany-limitations of the 'sickest first'-concept. Transpl Int 2011; 24: 91-99.
19. Silva MF, Sherman M,. Criteria for liver transplantation for HCC: what should the limits be? J Hepatol 2011; 55: 1137-1147.
20. Wiesner RH, Fung JJ,. Present state of immunosuppressive therapy in liver transplant recipients. Liver Transpl 2011 Nov;17 Suppl 3: S1-S9.
21. Eason JD, Nair S, Cohen AJ, Blazek JL, Loss GE Jr,. Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy. Transplantation 2003; 75: 1396-1399.
22. Nair S, Loss GE, Cohen AJ, Eason JD,. Induction with rabbit antithymocyte globulin versus induction with corticosteroids in liver transplantation: impact on recurrent hepatitis C virus infection. Transplantation 2006; 81: 620-622.
23. Tchervenkov JI, Tzimas GN, Cantarovich M, Barkun JS, Metrakos P,. The impact of thymoglobulin on renal function and calcineurin inhibitor initiation in recipients of orthotopic liver transplant: a retrospective analysis of 298 consecutive patients. Transplant Proc 2004; 36: 1747-1752.
24. Tector AJ, Fridell JA, Mangus RS, Shah A, Milgrom M, Kwo P, et al. Promising early results with immunosuppression using rabbit anti-thymocyte globulin and steroids with delayed introduction of tacrolimus in adult liver transplant recipients. Liver Transpl 2004; 10: 404-407.
25. Soliman T, Hetz H, Burghuber C, Györi G, Silberhumer G, Steininger R, et al. Short-term induction therapy with anti-thymocyte globulin and delayed use of calcineurin inhibitors in orthotopic liver transplantation. Liver Transpl 2007; 13: 1039-1044.
26. Shah A, Agarwal A, Mangus R, Lim J, Fridell J, Vianna R, Tector AJ,. Induction immunosuppression with rabbit antithymocyte globulin in pediatric liver transplantation. Liver Transpl 2006; 12: 1210-1214.
27. Bajjoka I, Hsaiky L, Brown K, Abouljoud M,. Preserving renal function in liver transplant recipients with rabbit anti-thymocyte globulin and delayed initiation of calcineurin inhibitors. Liver Transpl 2008; 14: 66-72.
28. Uemura T, Schaefer E, Hollenbeak CS, Khan A, Kadry Z,. Outcome of induction immunosuppression for liver transplantation comparing anti-thymocyte globulin, daclizumab, and corticosteroid. Transpl Int 2011; 24: 640-650.
29. De Ruvo N, Cucchetti A, Lauro A, Masetti M, Cautero N, Di Benedetto F, et al. Preliminary results of a "prope" tolerogenic regimen with thymoglobulin pretreatment and hepatitis C virus recurrence in liver transplantation. Transplantation 2005; 80: 8-12.
30. Belli LS, Burroughs AK, Burra P, Alberti AB, Samonakis D, Cammà C, et al. Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study. Liver Transpl 2007; 13: 733-740.
31. Kamar N, Borde JS, Sandres-Saune K, Suc B, Barange K, Cointault O, et al. Induction therapy with either anti-CD25 monoclonal antibodies or rabbit antithymocyte globulins in liver transplantation for hepatitis C. Clin Transplant 2005; 19: 83-89.
32. Moonka DK, Kim D, Kapke A, Brown KA, Yoshida A,. The influence of induction therapy on graft and patient survival in patients with and without hepatitis C after liver transplantation. Am J Transplant 2010; 10: 590-601.
33. Lladõ L, Fabregat J, Castellote J, Ramos E, Xiol X, Torras J, et al.; for THOSIN Study Group. Impact of immunosuppression without steroids on rejection and hepatitis C virus evolution after liver transplantation: results of a prospective randomized study. Liver Transpl 2008; 14: 1752-1760.
34. Calmus Y, Scheele JR, Gonzalez-Pinto I, Jaurrieta EJ, Klar E, Pageaux GP, et al. Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients. Liver Transpl 2002; 8: 123-131.
35. Filipponi F, Callea F, Salizzoni M, Grazi GL, Fassati LR, Rossi M, et al. Double-blind comparison of hepatitis C histological recurrence rate in HCV+ liver transplant recipients given basiliximab + steroids or basiliximab + placebo, in addition to cyclosporine and azathioprine. Transplantation 2004; 78: 1488-1495.
36. Neuhaus P, Clavien PA, Kittur D, Salizzoni M, Rimola A, Abeywickrama K, et al.; for CHIC 304 International Liver Study Group. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial. Liver Transpl 2002; 8: 132-142.
37. Klintmalm GB, Davis GL, Teperman L, Netto GJ, Washburn K, Rudich SM, et al. A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transpl 2011; 17. 1394-1403.
38. Nelson DR, Soldevila-Pico C, Reed A, Abdelmalek MF, Hemming AW, Van der Werf WJ, et al. Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation. Liver Transpl 2001; 7: 1064-1070.
39. Sánchez-Fueyo A, Strom TB,. Immunological tolerance and liver transplantation. J Hepatol 2004; 41: 698-705.
40. Starzl TE, Murase N, Abu-Elmagd K, Gray EA, Shapiro R, Eghtesad B, et al. Tolerogenic immunosuppression for organ transplantation. Lancet 2003; 361: 1502-1510.
41. Benítez CE, Puig-Pey I, Lõpez M, Martínez-Llordella M, Lozano JJ, Bohne F, et al. ATG-Fresenius treatment and low-dose tacrolimus: results of a randomized controlled trial in liver transplantation. Am J Transplant 2010; 10: 2296-2304.